Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

The US drugmaker Eli Lilly has bowed to demands from Donald Trump by raising the prices of its weight-loss jab for UK ...

The injection was initially licensed to treat type 2 diabetes, but is now also prescribed to help with weight loss ...

Mounjaro, one of the UK’s most popular weight-loss jabs, is set to become more expensive for private patients after Eli Lilly ...

Uncover the truth about GLP-1 weight loss drugs like Ozempic and Mounjaro. Learn how they work, who benefits most, potential risks, and why experts say they can be game-changing tools for fighting ...

Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s | ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...